Changes

no edit summary
Line 2: Line 2:     
#To become a curator, contact ccga@cancergenomics.org to request access to the CCGA site.  You will also be connected with an Associate Editor.
 
#To become a curator, contact ccga@cancergenomics.org to request access to the CCGA site.  You will also be connected with an Associate Editor.
#Choose or be assigned a few GENE pages to curate.
+
#Choose or be assigned a few gene pages to curate.
#Read this tutorial and curate the page by reviewing appropriate related literature and authoring content on the GENE page (DO NOT PLAGIARIZE!)
+
#Read this tutorial and curate the page by reviewing appropriate related literature and authoring content on the gene page (DO NOT PLAGIARIZE!)
#Contact the Associate Editor for questions and upon completion of GENE page curation.
+
#Contact the Associate Editor for questions and upon completion of gene page curation.
    
==Introduction:==
 
==Introduction:==
Line 12: Line 12:     
==Associate Editor:==
 
==Associate Editor:==
Your curation of the gene and protein information will be aided and reviewed by an assigned Associate Editor. Please note that this written document cannot cover all the questions and decisions your will be faced with as you curate.  Therefore, PLEASE feel free to contact your Associated Editor with any questions and upon completion of a page.
+
Your curation of the gene and protein information will be aided and reviewed by an assigned Associate Editor. Please note that this written document cannot cover all the questions and decisions your will be faced with as you curate.  Therefore, PLEASE feel free to contact your Associate Editor with any questions and upon completion of a page.
    
==Gene Pages:==
 
==Gene Pages:==
'''''QUESTION: do we need to designate Genes as Drivers vs. passengers?'''''
+
You will be asked to choose the gene pages you wish to curate from this list: http://www.ccga.io/index.php/List_of_Gene_Pages.
 +
A “Gene specific Template” has been added to these pages for you to use to add your curated information.
   −
You will be asked to choose from a number gene pages that you would like to curate. See list here: http://www.ccga.io/index.php/List_of_Gene_Pages
+
Note: The gene pages template already has the required headers, links and other syntaxPlease do not change the syntax of the template so there is consistency between similar pages.
A “Gene specific Template” has been produced which provides you with very nice Media Wiki Template to fill in with information you have curatedIt is shown here. http://www.ccga.io/index.php/Gene-Specific_Template. 
     −
Note that the Template already has the markup language you will need for headers, links, and other syntax to be used in the Gene PaesPlease do not change the syntax of the template, so users of the CCGA pages will want to see the same format from page to page.
+
Note: Save edits to your page frequently or produce content in a Word format of the template and add it into the wiki site subsequentlyFor a Word document template for authoring a <u>'''gene-specific page'''</u> before transferring content online please see [[File:Gene-Specific Template Word Version (9-28-21).docx|none|thumb|Gene-Specific Template]].  
   −
NOTE:  When you do large edits on a Wiki page, the security makes sure yo are a human with test at the top of the page and a simple mathematical formula you must complete, as below. YOU MUST answer the mathematical equation for your edits to be saved.
+
NOTE:  When you do large edits on a Wiki page, the security makes sure you are a human with test at the top of the page and a simple mathematical formula you must complete, as below. YOU MUST answer the mathematical equation for your edits to be saved.
    
''Your edit includes new external links. To protect the wiki against automated spam, we kindly ask you to solve the following task below and enter the answer in the box in order to save your edit (more info):  45−1 =''
 
''Your edit includes new external links. To protect the wiki against automated spam, we kindly ask you to solve the following task below and enter the answer in the box in order to save your edit (more info):  45−1 =''
   −
==Gene curation using the “Gene specific Template” MediaWiki Template in CCGA==
+
==Gene Curation Using the “Gene-Specific Template” in CCGA==
In most cases, the Gene you will curate has already been created, based on the Gene specific template. However, if not, you will need to copy the Gene specific template to a new page.
     −
#Go to the gene specific template (http://www.ccga.io/index.php/Gene-Specific_Template )
+
The template provides an easy "fill in the blanks" WikiMedia page which already has formatted markups (for headers) and has examples for you to follow.  The Template is described briefly below.  
#Click “edit source” link at top center-right of page
  −
#Copy the entire page (eg on a Mac, “command (cmd) a”, and then “cmd c”
  −
#Open in another browser window the gene page you will curate
  −
#Paste in the template (cmd v) and then save (at bottom of page)
  −
 
  −
The template provides an easy "fill in the blanks" WikiMedia page which already has formatted markups (for headers) and has examples for you to follow.  The Template is described briefly, below.  
      
Sections:   
 
Sections:   
Line 147: Line 140:  
The example of RUNX1 is shown below.
 
The example of RUNX1 is shown below.
   −
*'''[http://www.ccga.io/index.php/Acute_Myeloid_Leukemia_(AML)_and_Related_Precursor_Neoplasms Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms]'''
+
*'''[http://www.ccga.io/index.php/HAEM4:Acute_Myeloid_Leukemia_(AML)_and_Related_Precursor_Neoplasms Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms]'''
   −
--- '''[http://www.ccga.io/index.php/Acute_Myeloid_Leukemia_(AML)_with_t(8;21)(q22;q22.1);_RUNX1-RUNX1T1 Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1]'''
+
--- '''[http://www.ccga.io/index.php/HAEM5:Acute_myeloid_leukaemia_with_RUNX1::RUNX1T1_fusion Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1]'''
   −
--- '''[http://www.ccga.io/index.php/Acute_Myeloid_Leukemia_(AML)_with_Mutated_RUNX1 Acute Myeloid Leukemia (AML) with Mutated RUNX1]'''
+
--- '''[http://www.ccga.io/index.php/HAEM4:Acute_Myeloid_Leukemia_(AML)_with_Mutated_RUNX1 Acute Myeloid Leukemia (AML) with Mutated RUNX1]'''
    
The frequency of ''RUNX1'' mutations is between 5-18% of all AML patients tested [3]. The most common chromosomal translocation is t(8;21)(q22;q22)resulting in RUNX1-RUNX1T1 fusion in ''de novo'' AML, at approximately 7% [2,6].  This translocation confers a favorable prognosis in AML and other neoplasms [2,5,6].  Another ''RUNX1'' alteration is the t(3;21)(q26;q22), in which the RUNT domain of ''RUNX1'' is fused to the entire ''EVI1'' gene.  This translocation is rarely found in patients diagnosed with ''de novo'' AML and is more common in those with therapy-related myelodysplastic syndrome (MDS)/AML [9].  Other mutations in ''RUNX1'' include deletions, missense, splicing, frameshift, and nonsense alterations (mostly loss-of-function or decreased function), and occur at a frequency of approximately 10% in AML patients [6]. These mutations are mechanistically distinct from the chromosomal translocations and confer a worse prognosis [2,5,6].
 
The frequency of ''RUNX1'' mutations is between 5-18% of all AML patients tested [3]. The most common chromosomal translocation is t(8;21)(q22;q22)resulting in RUNX1-RUNX1T1 fusion in ''de novo'' AML, at approximately 7% [2,6].  This translocation confers a favorable prognosis in AML and other neoplasms [2,5,6].  Another ''RUNX1'' alteration is the t(3;21)(q26;q22), in which the RUNT domain of ''RUNX1'' is fused to the entire ''EVI1'' gene.  This translocation is rarely found in patients diagnosed with ''de novo'' AML and is more common in those with therapy-related myelodysplastic syndrome (MDS)/AML [9].  Other mutations in ''RUNX1'' include deletions, missense, splicing, frameshift, and nonsense alterations (mostly loss-of-function or decreased function), and occur at a frequency of approximately 10% in AML patients [6]. These mutations are mechanistically distinct from the chromosomal translocations and confer a worse prognosis [2,5,6].
Line 239: Line 232:  
'''[http://www.ccga.io/index.php/Acute_lymphoblastic_leukaemia_(ALL) Acute Lymphoblastic Leukemia]'''
 
'''[http://www.ccga.io/index.php/Acute_lymphoblastic_leukaemia_(ALL) Acute Lymphoblastic Leukemia]'''
   −
'''[http://www.ccga.io/index.php/Acute_Myeloid_Leukemia_(AML)_with_BCR-ABL1 Acute Myeloid Leukemia (AML) with BCR-ABL1]'''
+
'''[http://www.ccga.io/index.php/HAEM5:Acute_myeloid_leukaemia_with_BCR::ABL1_fusion Acute Myeloid Leukemia (AML) with BCR-ABL1]'''
   −
'''[http://www.ccga.io/index.php/Mixed_Phenotype_Acute_Leukemia_(MPAL)_with_t(9;22)(q34.1;q11.2);_BCR-ABL1 Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1]'''
+
'''[http://www.ccga.io/index.php/HAEM5:Mixed-phenotype_acute_leukaemia_with_BCR::ABL1_fusion Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1]'''
    
See the '''[http://www.ccga.io/index.php/BCR "BCR gene"]''' for additional details of the BCR-ABL1 gene fusion.
 
See the '''[http://www.ccga.io/index.php/BCR "BCR gene"]''' for additional details of the BCR-ABL1 gene fusion.
Line 259: Line 252:  
#“WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.pdf” Download from http://publications.iarc.fr/_publications/media/download/1511/700ac655d7f248cf1044efd985275086ed4f341f.pdf
 
#“WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.pdf” Download from http://publications.iarc.fr/_publications/media/download/1511/700ac655d7f248cf1044efd985275086ed4f341f.pdf
    +
==<big>FAQ (Frequently Asked Questions)</big>==
   −
+
'''''QUESTION:  Do we need to designate Genes as Drivers vs. Passengers?'''''
==<big>FAQ (Frequently Asked Questions)</big>==